Mobile

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005084-34

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK PS Study. Revised Protocol 02 incorporating Protocol Amendment 09 and Administrative Letter 01 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (v1.0, dated 12-Sep-2008)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (BSC) to those receiving placebo plus BSC.

Critère d'inclusion

  • Advanced Hepatocellular Carcinoma

Liens